Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IIb Study on the Safety and Efficacy of BM32, a Recombinant Hypoallergenic Vaccine for Immunotherapy of Grass Pollen Allergy

NCT01538979 is registered in ClinicalTrials.gov with Biomay AG as lead sponsor.

NCT NCT01538979
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01538979 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IIb Study on the Safety and Efficacy of BM32, a Recombinant Hypoallergenic Vaccine for Immunotherapy of Grass Pollen Allergy
Lead sponsor
Biomay AG
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2012
Completion date
March 31, 2015
Enrollment
181 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

grass pollen allergy